

THE ITALIAN NON PROFIT TRANSLATIONAL BIOTECH FOUNDATION

FOUNDING PARTNERS

Presidency of the Italian Council of Ministers; University of Pittsburgh; UPMC (University of Pittsburgh Medical Center); Italian National Research Council (CNR); Region of Sicily.

PARTNERSHIPS


Thanks to powerful international strategic alliances with the founding partners and IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Ri.MED is focused on integrating biomedical research progress into patient care by translating new findings in preclinical drug discovery, regenerative medicine, and tissue engineering into clinical applications for diagnosis, treatment, and disease prevention.

MISSION

Promote, support, and conduct biotech and biomedical research projects to rapidly transfer innovative discoveries into clinical practice.

Promote and sustain the development of the biotech sector in Sicily and south of Italy in order to position the country at the forefront in this research sector.

RI.MED POSITIONING IN THE LIFE SCIENCE SECTOR



RI.MED FOUNDING PARTNERS











PLEASE NOTE:

- The official language of the scientific talks is English.
- Attendance is free, but admission will be allowed according to maximum seating availability of the room.
- Please fill out the registration form at www.fondazionerimed.eu by October 9, 2016.





Via Bandiera, 11 - 90133 Palermo, Italy Tel. + 39 0916041111 - Fax + 39 0916041122 www.fondazionerimed.com





10th ANNUAL RI.MED SCIENTIFIC SYMPOSIUM

BRIDGING HEALTH AND ECONOMIC DEVELOPMENT THROUGH PUBLIC-PRIVATE PARTNERSHIPS



Monday 17 | October 2016

Grand Hotel Villa Igiea Centro Congressi Salita Belmonte, 43 90142 Palermo - Italy

ECM accredited event

10th ANNUAL RI.MED SCIENTIFIC SYMPOSIUM

BRIDGING HEALTH AND ECONOMIC DEVELOPMENT THROUGH PUBLIC-PRIVATE PARTNERSHIPS

The public and private sectors have joined forces to develop and deliver health care solutions that both improve patients' lives and also have a measurable economic impact. This innovative partnership model includes the participation of governments, universities, research institutes, medical centers, industry, and patients themselves-all playing an active role in addressing a common goal.

Based on an Italy-U.S. scientific cooperation agreement, the Ri.MED Foundation was established as a non profit organization dedicated to promoting biomedical research and development, with its application to biotechnology, and having a particular focus in Sicily and the south of Italy.

The integration of Ri.MED with the IRCCS ISMETT has enabled affiliated scientists to further the development of a diversified pipeline of preclinical products based on innovative approaches such as regenerative medicine, tissue engineering, and the application of quantitative systems pharmacology to drug discovery.

The 10th Ri.MED Symposium will exemplify international collaborative programs that demonstrate synergistic and integrated contributions from preclinical research through clinical application and regional economic development.

OGRAM	MONDAY, 17 OCTOBER 2016
08:30 am	Symposium Registration
09:00 am	Welcome and Introduction Camillo Ricordi, MD - Bruno Gridelli, MD - Alessandro Padova, PhD, CEO Arthur S. Levine, MD
09:30 am	Cardiac Regeneration: Advanced Diagnostic Tools & Novel Tissue Engineering Approaches Salvatore Pasta, PhD - Cesare Scardulla, MD - Antonio D'Amore, PhD
10:30 am	Biomaterials and Micro-Bioreactors William R. Wagner, PhD - Riccardo Gottardi, PhD
11:15 am	Coffee Break
11:30 am	Transitioning a Redox-Derived Endogenous Signaling Mediator to a New Drug Class - Nitro-Fatty Acids Bruce Freeman, PhD - Marco Fazzari, PhD - Chiara Cipollina, PhD
12:15 pm	Frontiers in the Treatment of Type 1 Diabetes Mariangela Pampalone - Anna Casu, MD - Giacomo Lanzoni, PhD
01:30 pm	Lunch
02:15 pm	Open challenges for Vaccine Development Bruno Douradinha, MD - Alessandra Mularoni, MD
03:00 pm	Coffee Break
03:30 pm	New Therapeutic Targets for Neurodegenerative Diseases Pierangelo Cifelli, MD, PhD - Roberto DiMaio, PhD - Andrea Caricasole, PhD
04:30 pm	Case History on OCALIVA (Obeticholic Acid), an FXR Receptor Agonist as a New Therapy for Primary Biliary Cirrhosis (PBC) and Related Liver Diseases Roberto Pellicciari, PhD
05:15 pm	Final Discussion & Symposium Adjournment

SPEAKERS

Andrea Caricasole, PhD

Drug Discovery Institute, University of Cambridge, UK

Anna Casu, MD

Diabetologist, IRCCS ISMETT, Palermo

Pierangelo Cifelli, MD, PhD

Ri.MED Supported Scientist Department of Physiology and Pharmacology "V. Erspamer," University "La Sapienza", Roma

Chiara Cipollina, PhD

Ri.MED Supported Scientist Institute of Biomedicine and Molecular Immunology (IBIM), Italian National Research Council (CNR)

Roberto Di Maio, PhD

Ri.MED Supported Scientist
Research Associate, Department of Neurology
University of Pittsburgh School of Medicine

Bruno G.M. Douradinha, PhD

Ri.MED Supported Scientist
Research Associate, Department of Microbiology
and Molecular Genetics
University of Pittsburgh School of Medicine

Antonio D'Amore. PhD

Ri.MED Supported Scientist Research Associate, Department of Surgery University of Pittsburgh School of Medicine

Marco Fazzari. PhD

Ri.MED Supported Scientist Research Associate, Department of Pharmacology and Chemical Biology University of Pittsburgh School of Medicine

Bruce A. Freeman. PhD

UPMC-Irwin Fridovich Professor and Chair Department of Pharmacology and Chemical Biology University of Pittsburgh School of Medicine

Riccardo Gottardi. PhD

Ri.MED Supported Scientist Research Associate, Department of Orthopaedic Surgery University of Pittsburgh School of Medicine

Bruno Gridelli, MD

Vice-President, Ri.MED Foundation
Professor of Surgery, University of Pittsburgh
School of Medicine
Vice President, UPMC International Division

Giacomo Lanzoni, PhD

Postdoctoral Research Associate Diabetes Research Institute Leonard M. Miller School of Medicine University of Miami

Arthur S. Levine, MD

Scientific Director, Ri.MED Foundation Senior Vice Chancellor for the Health Sciences John and Gertrude Petersen Dean of Medicine Professor of Medicine and of Molecular Genetics University of Pittsburgh

Alessandra Mularoni, MD

Infectologist
IRCCS ISMETT, Palermo

Alessandro Padova, PhD, CEO

Director General, Ri.MED Foundation

Mariangela Pampalone

Ri.MED-Supported Scientist
Regenerative Medicine and Biomedical Technology Unit
IRCCS ISMETT

Salvatore Pasta, PhD

Ri.MED Supported Scientist
Department of Chemical, Management, Computer and
Mechanical Engineering, University of Palermo

Roberto Pellicciari. PhD

President and CSO TES Pharma Srl, Perugia, Italy

Camillo Ricordi, MD

President, Ri.MED Foundation
Stacy Joy Goodman Professor of Surgery
Distinguished Professor of Medicine, Professor of
Biomedical Engineering, of Microbiology, and of
Immunology
Director, Cell Transplant Program and Diabetes
Research Institute

University of Miami Cesare Scardulla, MD

Leonard M. Miller School of Medicine

Cardiologist, IRCCS ISMETT, Palermo, Italy

William R. Wagner, PhD Professor of Surgery

University of Pittsburgh

School of Medicine
Professor of Bioengineering and of Chemical Engineering
Swanson School of Engineering
Director, McGowan Institute for Regenerative Medicine,